Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 18 of 18 results for peginterferon alfa

  1. Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)

    Evidence-based recommendations on chlormethine gel (Ledaga) for treating early-stage mycosis fungoides-type cutaneous T-cell lymphoma in adults.

    Technology appraisal guidance
    Published
    18 August 2021
    View recommendations

    Sections for TA720

  2. Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (TA331)

    The guidance has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.

    Technology appraisal guidance
    Published
    25 February 2015

  3. Bulevirtide for treating chronic hepatitis D (TA896)

    Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.

    Technology appraisal guidance
    Published
    7 June 2023
    View recommendations

    Sections for TA896